<?xml version="1.0" encoding="utf-8" ?>
<INTERACTIONS>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>205-ENOXACIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ENOXACIN" rxcui="3925">
<ATC code="J01MA04" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="CAFFEINE " rxcui="1886">
<ATC code="V04CG30" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of caffeine, which can lead to agitation and hallucinations, due to decrease of its hepatic metabolism</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>205-ENOXACIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ENOXACIN" rxcui="3925">
<ATC code="J01MA04" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="DULOXETINE" rxcui="72625">
<ATC code="N06AX21" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the undesirable effects of the duloxetine due to decrease of its hepatic metabolism by the exnoxacin</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>205-ENOXACIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ENOXACIN" rxcui="3925">
<ATC code="J01MA04" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ROPINIROLE" rxcui="72302">
<ATC code="N04BC04" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of ropinirole with signs of overdose due to decrease of its hepatic metabolism</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and reduction of the dosage of the ropinirole during the treatment with the enoxacin and after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>205-ENOXACIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ENOXACIN" rxcui="3925">
<ATC code="J01MA04" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)" code="R03DA" /></DRUG2>
<DESCRIPTION>Overdose of theophylline due to substantial decrease of its metabolism</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
</INTERACTIONS>
